SecurityOCIP / OCI Partners LP (67091N108)
IndustryChemicals And Allied Products
Institutional Owners22
Institutional Shares76,725,550 - 88.19%
Common Shares Outstanding86,997,590 shares (as of 2018-03-31)
Institutional Value$ 66,150,000 USD

Institutional Stock Ownership and Shareholders()

OCIP / OCI Partners LP Institutional Ownership

OCI Partners LP (NYSE:OCIP) has 22 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 76,725,550 shares. Largest shareholders include Oci N.v., Morgan Stanley, Cowen Group, Inc., UBS Group AG, PCJ Investment Counsel Ltd., Bard Associates Inc, Credit Capital Investments LLC, Quinn Opportunity Partners LLC, Deutsche Bank Ag\, and Renaissance Technologies LLC.
OCI Partners LP (NYSE:OCIP) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ocip"><img src="https://images.fintel.io/us-ocip-so.png" alt="OCIP / OCI Partners LP Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR BARCLAYS PLC 58 58 0.00 0 1
2018-05-16 13F-HR/A COWEN GROUP, INC. 402,162 710,763 76.74 3,237 6,503 100.90
2016-12-06 SC 13D/A OCI N.V. 69,497,590 69,497,590 0.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 27,067 0 -100.00 218 0 -100.00
2018-05-14 13F-HR NFC Investments, LLC 203,925 0 -100.00 1,642 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 35,896 36,200 0.85 288 331 14.93
2018-05-14 13F-HR ICONIQ Capital, LLC 17,835 17,835 0.00 144 168 16.67
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 0 2,942 0 27
2018-05-15 13F-HR UBS Group AG 357,606 357,606 0.00 2,879 3,272 13.65
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 14,024 13,824 -1.43 113 126 11.50
2018-05-14 13F-HR PCJ Investment Counsel Ltd. 63,900 150,000 134.74 514 1,372 166.93
2018-05-11 13F-HR CITIGROUP INC 1,842 1,842 0.00 15 17 13.33
2018-05-14 13F-HR MORGAN STANLEY 10,697,559 5,572,390 -47.91 86,115 50,988 -40.79
2018-05-15 13F-HR Credit Capital Investments LLC 70,300 70,300 0.00 566 643 13.60
2018-05-14 13F-HR Quinn Opportunity Partners LLC 69,235 69,235 0.00 557 634 13.82
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 2,584 2,584 0.00 21 24 14.29
2018-05-14 13F-HR BARD ASSOCIATES INC 143,975 149,675 3.96 1,159 1,370 18.21
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 2,500 2,500 0.00 20 23 15.00
2017-01-13 13F-HR MetLife Securities, Inc 455 455 0.00 3 4 33.33
2018-05-25 13F-HR/A Worth Venture Partners, LLC 12,540 115
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 1 1 0.00 8 9 12.50
2018-05-15 13F-HR Walleye Trading LLC 12,400 12,400 0.00 100 113 13.00
2018-05-14 13F-HR Renaissance Technologies LLC 27,178 33,256 22.36 219 304 38.81
2018-05-11 13F-HR DELTEC ASSET MANAGEMENT LLC 11,554 11,554 0.00 93 106 13.98

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

41 'Safer' Basic Materials Top Yielding Dividends For June

2018-06-14 seekingalpha
41 of 87 Basic Materials top yield stocks were tagged "safer" for dividends because they showed positive annual returns and free cash flow yields greater than their dividend yields. (47-0)

Market Considers Pardon For Midstream

2018-06-10 seekingalpha
Midstream corporations and MLPs finished roughly where they started this week. But along the way, on Thursday, both AMZ and AMEI reached their highest levels since mid-February. The gains through Thursday slipped away Friday and the MLP Index closed back at its 200-day moving average. Midstream held up in a bad week (within a bad year) for income securities like utilities. (38-0)

OCI Partners' (OCIP) CEO Ahmed El-Hoshy on Q1 2018 Results - Earnings Call Transcript

2018-05-07 seekingalpha
Good morning. My name is Adam, and I’ll be your conference operator today. At this time, I would like to welcome everyone to the OCI Partners LP 2018 First Quarter Results Conference Call. [Operator Instructions] Thank you.

BRIEF-OCI Partners Says Q1 Revenue Rose 26 Pct To $117 Mln

2018-05-07 reuters
* OCI PARTNERS - QTRLY NET INCOME INCREASED TO $30 MILLION VERSUS $14 MILLION LAST YEAR Source text for Eikon: Further company coverage:

CUSIP: 67091N108